Expanse Ice recently announced that its Ice aspiration system has received 510(k) clearance from the US Food and Drug Administration (FDA).
A press release notes that the Ice system is specifically designed to address the complex challenges associated with peripheral thrombectomies.
Eitan Konstantino, a serial entrepreneur in the vascular device field, is the driving force behind Expanse Ice. “We’ve engineered the Ice catheter system to harness the aspiration power typical of a large bore catheter, but within the slender profile of a much smaller device,” Konstantino said.
“It is clear this device was built with physicians in mind. It aims to address some of the biggest issues we see regularly. The device was designed and built with a strong understanding of foundational physics that leaves me optimistic for its success,” said Michael Lichtenberg, chief medical officer of angiology at the Vascular Center Clinic in Arnsberg, Germany.
“I am looking forward to being among the first users of the Expanse Ice system. Its ability to offer powerful clot removal in a compact size is an intriguing proposition that could significantly enhance our ability to meet patient needs more effectively and improve treatment outcomes in peripheral vascular disease,” said Aravinda Nanjundappa, director of peripheral vascular interventions at the Cleveland Clinic in Cleveland, USA.
“The thrombectomy market is witnessing robust growth and the approval of the Ice system comes at an auspicious time. It is cutting-edge technology in an underpenetrated market,” said Shlomi Nachman, former Johnson & Johnson Company group chairman of cardiovascular and specialty solutions and vision.
